ABSTRACT
To prevent antimicrobial resistance and inform better, antibiograms should distinguish different biomedical situations. It is also desirable that new antibiograms provide in vivo, temporal, and patient-specific immunological information. Here, the informative ability of a pattern recognition-based method was explored with data collected from patients that experienced seven infectious syndromes (pneumonia, endocarditis, tuberculosis, syphilis, as well as skin and soft tissue, intra-abdominal, and/or urinary tract infections associated with meningitis). Interactions among seven dimensions (7D) were investigated: (i) space, (ii) time, (iii) temporal data directionality, (iv) immunological multicellularity, (v) antibiotics, (vi) immunomodulation, and (vii) personalized data. Omissions and ambiguity (confounding different biological situations) occurred when static metrics were used in isolation, such as leukocyte percentages. In contrast, hidden information was uncovered when complexity and dynamics were assessed. The 7D approach grouped together observations that displayed similar immune profiles and identified antibiotics that modulated specific leukocytes. For instance, in tuberculosis, blood monocytes were modulated by isoniazid-related antimicrobials. In spite of the diverse syndromes analyzed, this proof-of-concept discriminated. It is suggested that the simultaneously exploration of numerous dimensions associated with complexity may be biologically interpretable, prevent ambiguity, promote research, expand machine learning-oriented methods, and support personalized medicine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted as described in Protocol #13-463, which was approved by the Institutional Research Protection Office committee of the Health Sciences Center, University of New Mexico on June 23, 2016 (protocol titled 'Small Dataset-Based Discrimination of Infectious Disease Pattern', Dr. M Iandiorio, PI). This protocol protects the identity of the patients investigated. The data were anonymized by a double-blind process in which the treating clinician does not participate in the analysis of the data and the data analyst does not receive any information that could identify the patients. Because this protocol allows the retrieval and analysis of clinical data from historical clinical records without a previous review, no waiver was requested and no decision from the competent authority was required in advance for any one study. The identification numbers reported in this study were created by the analyst in order to perform the analysis ̶ they do not / cannot identify any person.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.